Search results - ORA - Oxford University Research Archive

1

Journal article

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial

Gossec, L, Coates, LC, Gladman, DD, et al.
2024-08-20

2

Journal article

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group

Leung, Y-Y, Tillett, W, de Wit, M, et al.
2023-11-01

3

Journal article

Proceedings of the GRAPPA 2022 executive retreat

Ng, B, Jadon, D, Adebajo, A, et al.
2023-11-01

4

Journal article

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

Coates, LC, Mease, P, Kronbergs, A, et al.
2022-06-08

5

Journal article

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial

Baraliakos, X, Pournara, E, Gossec, L, et al.
2022-07-18

6

Journal article

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

Coates, L, Mease, P, Kronbergs, A, et al.
2022-06-08

7

Journal article

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Poddubnyy, D, Baraliakos, X, Van den Bosch, F, et al.
2021-12-18

8

Journal article

Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study

Coates, LC, Tillett, W, D’Agostino, MA, et al.
2022-02-25

9

Journal article

Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study

Skougaard, M, Jørgensen, TS, Jensen, MJ, et al.
2021-11-02

10

Journal article

OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF

Leung, Y-Y, Orbai, A-M, Hojgaard, P, et al.
2021-07-24

11

Journal article

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis

Leung, YY, Tillett, W, Hojgaard, P, et al.
2021-04-15

12

Journal article

Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative

Antony, A, Holland, R, D'Agostino, M-A, et al.
2021-02-11

13

Journal article

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis

Leung, YY, Orbai, A-M, Ogdie, A, et al.
2020-02-01

14

Journal article

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review

Leung, Y-Y, Holland, R, Mathew, AJ, et al.
2020-06-18

15

Journal article

Measuring outcomes in psoriatic arthritis

Ogdie, A, Coates, LC, Mease, P
2020-10-22

16

Journal article

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps

Tillett, W, McHugh, N, Orbai, AM, et al.
2020-06-01

17

Journal article

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Coates, L, Wallman, J, McGonagle, D, et al.
2019-12-04

18

Journal article

Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 psoriatic arthritis workshop report

Duarte-García, A, Leung, Y, Coates, L, et al.
2019-08-01

19

Journal article

Measurement properties of the minimal disease activity criteria for psoriatic arthritis

Coates, L, Strand, V, Wilson, H, et al.
2019-09-06

20

Journal article

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 annual meeting: report and plan for completing the core outcome measurement set

Leung, Y, Orbai, A, Ogdie, A, et al.
2019-06-01

21

Journal article

International treatment recommendations update: A report from the GRAPPA 2016 annual meeting

Coates, L, Chandran, V, Ogdie, A, et al.
2017-05-01

22

Journal article

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

Mease, P, Kavanaugh, A, Coates, L, et al.
2017-07-18

23

Journal article

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis

Coates, L, Gossec, L, Ramiro, S, et al.
2017-01-11

24

Journal article

GRAPPA 2016 Project Report

Helliwell, P, Fitzgerald, O, Coates, L, et al.
2017-05-01

25

Conference item

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

Nash, P, Coates, L, Kivitz, A, et al.
2018-06-12

26

Conference item

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study

Nash, P, Coates, L, Kivitz, A, et al.
2018-10-15

27

Journal article

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis

Singh, J, Guyatt, G, Ogdie, A, et al.
2018-11-30

28

Conference item

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation

Taylor, P, Mease, P, Bushmakin, A, et al.
2019-05-27

29

Journal article

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis

Singh, J, Guyatt, G, Ogdie, A, et al.
2018-11-30

30

Journal article

PsAID12 provisionally endorsed at OMERACT 2018 as core outcome measure to assess psoriatic arthritis-specific health-related quality of life in clinical trials

Orbai, A, Holland, R, Leung, Y, et al.
2018-12-15

31

Journal article

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

Mease, P, Coates, L, Helliwell, P, et al.
2018-10-22

32

Conference item

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib

de Vlam, K, Ogdie, A, Bushmakin, A, et al.
2018-10-15

33

Conference item

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis

Ogdie, A, de Vlam, K, Bushmakin, A, et al.
2018-10-15

34

Journal article

Classification and outcome measures for psoriatic arthritis

Leung, Y, Ogdie, A, Orbai, A, et al.
2018-09-06

35

Journal article

Remission in psoriatic arthritis—where are we now?

Coates, L, Conaghan, P, D'Agostino, M, et al.
2017-10-16

36

Journal article

Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting

Holland, R, Tillett, W, Ogdie, A, et al.
2018-06-01

37

Journal article

GRAPPA 2017 Project Report

Callis Duffin, K, FitzGerald, O, Kavanaugh, A, et al.
2018-06-01

38

Journal article

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Coates, L, Kishimoto, M, Gottlieb, A, et al.
2017-12-22

39

Journal article

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)

Mease, P, Gladman, D, Samad, A, et al.
2018-02-03

40

Journal article

Considerations for the definition of remission criteria in psoriatic arthritis

Mease, P, Coates, L
2017-10-31

41

Journal article

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study

Coates, L, Mease, P, Gossec, L, et al.
2018-02-06

42

Journal article

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Smolen, JS, Schöls, M, Braun, J, et al.
2017-07-06

43

Journal article

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus‐based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis

Coates, L, FitzGerald, O, Merola, J, et al.
2017-11-26

44

Journal article

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies

Tillett, W, Orbai, A, Ogdie, A, et al.
2017-07-26

45

Conference item

Adalimumab enhances health-related quality of life in patients with active ankylosing spondylitis - Results from the atlas trial

van der Heijde, D, Luo, M, Matsumoto, A, et al.
2006-04-01

46

Conference item

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.

Lassere, M, Johnson, K, Boers, M, et al.
2007-03-01

47

Conference item

Adalimumab improves physical functioning and work productivity in ankylosing spondylitis (AS) patients: Results from ATLAS.

van der Heijde, D, Luo, M, Wordsworth, P, et al.
2006-09-01

48

Conference item

Improved physical functioning and work productivity in ankylosing spondylitis (AS) patients who were treated with adalimumab-ATLAS trial results

Vanderheijde, D, Wordsworth, P, Luo, M, et al.
2007-04-01

49

Conference item

Improvements in health related quality of life (HRQL) correlate positively with clinical reponses in ankylosing spondylitis (AS) patients - Results from ATLAS

Van der Heijde, D, Luo, M, Davis, J, et al.
2006-07-01

50

Conference item

Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial.

Van der Heijde, D, Luo, M, Matsumoto, A, et al.
2005-09-01

EXPLORE THE UNIVERSITY OF OXFORD'S WORLD-CLASS RESEARCH